An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)
A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Sponsor: Childhood Liver Disease Research and Education Network
A PHASE2 clinical study on Alagille Syndrome, this trial is completed. The trial is conducted by Childhood Liver Disease Research and Education Network and has accumulated 16 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Childhood Liver Disease Research and Education Network
- Lumena Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .